Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB.
Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, Umaña P, Benincosa L, Bachl J, Singer T, Bray-French K. Dudal S, et al. Among authors: bray french k. J Immunother. 2016 Sep;39(7):279-89. doi: 10.1097/CJI.0000000000000132. J Immunother. 2016. PMID: 27404941
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice.
Egli J, Heiler S, Weber F, Steiner G, Schwandt T, Bray-French K, Klein C, Fenn S, Lotz GP, Opolka-Hoffmann E, Kraft TE, Petersen L, Moser R, DeGeer J, Siegel M, Finke D, Bessa J, Iglesias A. Egli J, et al. Among authors: bray french k. MAbs. 2022 Jan-Dec;14(1):2143009. doi: 10.1080/19420862.2022.2143009. MAbs. 2022. PMID: 36394299 Free PMC article.
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics.
Siegel M, Steiner G, Franssen LC, Carratu F, Herron J, Hartman K, Looney CM, Ducret A, Bray-French K, Rohr O, Hickling TP, Smith N, Marban-Doran C. Siegel M, et al. Among authors: bray french k. Pharmaceutics. 2022 Dec 1;14(12):2672. doi: 10.3390/pharmaceutics14122672. Pharmaceutics. 2022. PMID: 36559166 Free PMC article.
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P. Bacac M, et al. Among authors: bray french k. Clin Cancer Res. 2018 Oct 1;24(19):4785-4797. doi: 10.1158/1078-0432.CCR-18-0455. Epub 2018 May 1. Clin Cancer Res. 2018. PMID: 29716920
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Müller C, Jegg AM, Bröske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Rüttinger D. Cassier PA, et al. Lancet Oncol. 2015 Aug;16(8):949-56. doi: 10.1016/S1470-2045(15)00132-1. Epub 2015 Jul 12. Lancet Oncol. 2015. PMID: 26179200 Clinical Trial.
16 results